Dr. Sherman on the Role of Regorafenib in Liver Cancer

Morris Sherman, MD
Published: Friday, Jan 13, 2017



Morris Sherman, MD, PhD, professor of Medicine at University of Toronto, discusses the emergence of regorafenib (Stivarga) and how it fits into the treatment of hepatocellular carcinoma (HCC).

Sherman believes that regorafenib should be the standard second-line treatment after sorafenib (Nexavar). Currently, second-line treatments include chemoembolization, which is used beyond what is known to be effective, as it can cause liver disease deterioration, says Sherman.

One of the challenges in determining where regorafenib fits into HCC treatment is patient selection, as there are no data to determine which subset of patients will respond well to the drug, and this trial is still in its early stages.
 


Morris Sherman, MD, PhD, professor of Medicine at University of Toronto, discusses the emergence of regorafenib (Stivarga) and how it fits into the treatment of hepatocellular carcinoma (HCC).

Sherman believes that regorafenib should be the standard second-line treatment after sorafenib (Nexavar). Currently, second-line treatments include chemoembolization, which is used beyond what is known to be effective, as it can cause liver disease deterioration, says Sherman.

One of the challenges in determining where regorafenib fits into HCC treatment is patient selection, as there are no data to determine which subset of patients will respond well to the drug, and this trial is still in its early stages.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: Key Questions for the Use of Immunotherapy Throughout the Disease Continuum for NSCLC in an Era of Rapid DevelopmentSep 29, 20181.5
Provider and Caregiver Connection™: Addressing Patient Concerns While Managing GlioblastomaSep 29, 20182.0
Publication Bottom Border
Border Publication
x